Senti Bioscience Financials
Financial Health Signals
Senti Bioscience passes 2 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
For every $1 of reported earnings, Senti Bioscience generates $0.78 in operating cash flow (-$41.4M OCF vs -$52.8M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
This page shows Senti Bioscience (SNTI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Senti Bioscience generated $0 in revenue in fiscal year 2024. This represents a decrease of 100.0% from the prior year.
Senti Bioscience's EBITDA was -$57.2M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 35.8% from the prior year.
Senti Bioscience generated -$41.4M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 35.7% from the prior year.
Senti Bioscience reported -$52.8M in net income in fiscal year 2024. This represents an increase of 25.7% from the prior year.
Senti Bioscience earned $-12.03 per diluted share (EPS) in fiscal year 2024. This represents an increase of 24.9% from the prior year.
Senti Bioscience held $48.3M in cash against $0 in long-term debt as of fiscal year 2024.
Senti Bioscience had 5M shares outstanding in fiscal year 2024. This represents an increase of 5.7% from the prior year.
Senti Bioscience invested $34.4M in research and development in fiscal year 2024. This represents an increase of 6.9% from the prior year.
Senti Bioscience invested $26K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 99.8% from the prior year.
SNTI Income Statement
| Metric | Q3'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | $0 | $0 | $0 | $0-100.0% | $338K-63.9% | $937K-27.1% | $1.3M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $10.5M+35.3% | $7.8M-15.1% | $9.2M+4.2% | $8.8M-3.8% | $9.1M+0.3% | $9.1M+32.2% | $6.9M-2.6% | $7.1M |
| SG&A Expenses | $6.4M-20.4% | $8.1M+92.2% | $4.2M-44.1% | $7.5M-19.2% | $9.3M-1.3% | $9.4M+2.0% | $9.2M+0.6% | $9.2M |
| Operating Income | -$16.9M-4.8% | -$16.2M-21.0% | -$13.4M+18.1% | -$16.3M+12.8% | -$18.7M+57.4% | -$43.9M-188.9% | -$15.2M-1.5% | -$15.0M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | $0 | $0 | $0 | $0 | N/A | $0 | $0 | $0 |
| Net Income | -$18.1M-2871.5% | -$610K+94.6% | -$11.2M+7.5% | -$12.1M+83.0% | -$71.1M-376.2% | -$14.9M+20.2% | -$18.7M+0.1% | -$18.7M |
| EPS (Diluted) | $-0.69 | $-0.62+74.7% | $-2.45 | $-2.65 | $-8.01 | $-3.36+20.4% | $-4.22-904.8% | $-0.42 |
SNTI Balance Sheet
| Metric | Q3'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $52.7M-46.2% | $97.8M+12.6% | $86.9M-14.9% | $102.2M-14.5% | $119.5M-9.3% | $131.8M-8.3% | $143.6M-11.0% | $161.4M |
| Current Assets | $18.2M-69.2% | $59.0M+33.0% | $44.3M-20.3% | $55.7M-21.8% | $71.2M-9.9% | $79.0M+24.4% | $63.5M-21.1% | $80.5M |
| Cash & Equivalents | $12.2M-74.6% | $48.3M+204.4% | $15.9M-33.1% | $23.7M-34.0% | $35.9M-8.9% | $39.4M+7.3% | $36.8M+16.3% | $31.6M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | $567K-28.3% | $791K |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $44.6M-38.3% | $72.2M+68.8% | $42.8M-7.2% | $46.1M-12.3% | $52.6M+7.7% | $48.8M+5.7% | $46.2M-5.8% | $49.1M |
| Current Liabilities | $12.0M-8.5% | $13.1M+45.0% | $9.1M-5.6% | $9.6M-24.2% | $12.7M+25.3% | $10.1M-3.0% | $10.4M-19.0% | $12.9M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $8.1M-68.3% | $25.6M-41.9% | $44.1M-21.3% | $56.1M-16.2% | $66.9M-19.3% | $82.9M-14.9% | $97.4M-13.3% | $112.3M |
| Retained Earnings | -$344.1M-15.8% | -$297.1M-11.0% | -$267.7M-4.4% | -$256.5M-5.0% | -$244.3M-8.3% | -$225.6M-7.1% | -$210.7M-9.7% | -$192.0M |
SNTI Cash Flow Statement
| Metric | Q3'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$9.4M+30.1% | -$13.5M-61.8% | -$8.3M+28.6% | -$11.7M-66.0% | -$7.0M+54.2% | -$15.4M-12.5% | -$13.7M+16.1% | -$16.3M |
| Capital Expenditures | $0-100.0% | $11K | $0-100.0% | $15K+275.0% | $4K-99.8% | $1.9M-49.4% | $3.7M-43.6% | $6.5M |
| Free Cash Flow | -$9.4M+30.1% | -$13.5M-62.0% | -$8.3M+28.7% | -$11.7M-66.1% | -$7.0M+59.2% | -$17.2M+0.6% | -$17.3M+24.0% | -$22.8M |
| Investing Cash Flow | $0+100.0% | -$11K | $0+100.0% | -$15K-114.9% | $101K-99.5% | $21.1M+15.3% | $18.3M+293.0% | -$9.5M |
| Financing Cash Flow | $124K-99.8% | $51.3M | $0 | $0-100.0% | $556K+2517.4% | -$23K-108.2% | $281K+902.9% | -$35K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
SNTI Financial Ratios
| Metric | Q3'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | -12981.1%-11360.1pp | -1620.9%-457.3pp | -1163.6% |
| Net Margin | N/A | N/A | N/A | N/A | N/A | -4415.1%-2419.7pp | -1995.4%-539.6pp | -1455.8% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -34.4%-33.8pp | -0.6%+12.3pp | -12.9%-1.0pp | -11.8%+47.6pp | -59.5%-48.1pp | -11.3%+1.7pp | -13.0%-1.4pp | -11.6% |
| Current Ratio | 1.51-3.0 | 4.49-0.4 | 4.89-0.9 | 5.79+0.2 | 5.62-2.2 | 7.81+1.7 | 6.09-0.2 | 6.26 |
| Debt-to-Equity | 5.49+2.7 | 2.81+1.8 | 0.97+0.1 | 0.82+0.0 | 0.79+0.2 | 0.59+0.1 | 0.47+0.0 | 0.44 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | -5099.7%-3248.7pp | -1851.0%-77.2pp | -1773.8% |
Similar Companies
Frequently Asked Questions
What is Senti Bioscience's annual revenue?
Senti Bioscience (SNTI) reported $0 in total revenue for fiscal year 2024. This represents a -100.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Senti Bioscience's revenue growing?
Senti Bioscience (SNTI) revenue declined by 100% year-over-year, from $2.6M to $0 in fiscal year 2024.
Is Senti Bioscience profitable?
No, Senti Bioscience (SNTI) reported a net income of -$52.8M in fiscal year 2024.
What is Senti Bioscience's earnings per share (EPS)?
Senti Bioscience (SNTI) reported diluted earnings per share of $-12.03 for fiscal year 2024. This represents a 24.9% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Senti Bioscience's EBITDA?
Senti Bioscience (SNTI) had EBITDA of -$57.2M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Senti Bioscience's free cash flow?
Senti Bioscience (SNTI) generated -$41.4M in free cash flow during fiscal year 2024. This represents a 35.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Senti Bioscience's operating cash flow?
Senti Bioscience (SNTI) generated -$41.4M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Senti Bioscience's total assets?
Senti Bioscience (SNTI) had $97.8M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Senti Bioscience's capital expenditures?
Senti Bioscience (SNTI) invested $26K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Senti Bioscience spend on research and development?
Senti Bioscience (SNTI) invested $34.4M in research and development during fiscal year 2024.
How many shares does Senti Bioscience have outstanding?
Senti Bioscience (SNTI) had 5M shares outstanding as of fiscal year 2024.
What is Senti Bioscience's current ratio?
Senti Bioscience (SNTI) had a current ratio of 4.49 as of fiscal year 2024, which is generally considered healthy.
What is Senti Bioscience's debt-to-equity ratio?
Senti Bioscience (SNTI) had a debt-to-equity ratio of 2.81 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Senti Bioscience's return on assets (ROA)?
Senti Bioscience (SNTI) had a return on assets of -53.9% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Senti Bioscience's cash runway?
Based on fiscal year 2024 data, Senti Bioscience (SNTI) had $48.3M in cash against an annual operating cash burn of $41.4M. This gives an estimated cash runway of approximately 14 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Senti Bioscience's Piotroski F-Score?
Senti Bioscience (SNTI) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Senti Bioscience's earnings high quality?
Senti Bioscience (SNTI) has an earnings quality ratio of 0.78x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.